Abstract: Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue including continuously feeding the adipose tissue to the milling device; mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device by means of a multiplicity of blades of a rotor, wherein the blades are arranged in a spaced arrangement with respect to the overall direction of flow and the blades are moving about an axis of rotation, wherein the axis of rotation is provided essentially parallel to the overall direction of flow, continuously withdrawing the processed tissue comprising the separated cells from the milling device.

Abstract: Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue comprising: continuously feeding the adipose tissue to the milling device (2); mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device (2) by means of a multiplicity of blades (19) of a rotor (10), wherein the blades (19) are arranged in a spaced arrangement with respect to the overall direction of flow and the blades (19) are moving about an axis of rotation (18), wherein the axis of rotation (18) is provided essentially parallel to said overall direction of flow; continuously withdrawing the processed tissue comprising the separated cells from the milling device (2).

Abstract: The present invention relates to a biologically active placenta-derived liquid human substrate (hpS) comprising extracellular matrix (ECM) proteins, cytokines and growth factors and use thereof. The present invention also provides methods of producing a composition comprising biologically active placenta-derived liquid human substrate (hpS).

Abstract: This disclosure provides a method for measuring coagulation of blood or plasma samples using viscoelastic tests (VET) wherein the measuring is performed in the presence of immobilised endothelial cells.

Abstract: The present invention relates to a biomaterial comprising a cartilage graft scaffold substantially free of viable cells, wherein the cartilage graft scaffold exhibits a plural of notches in form of lamellae or grids.

Abstract: Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue comprising: continuously feeding the adipose tissue to the milling device (2); mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device (2) by means of a multiplicity of blades (19) of a rotor (10), wherein the blades (19) are arranged in a spaced arrangement with respect to the overall direction of flow and the blades (19) are moving about an axis of rotation (18), wherein the axis of rotation (18) is provided essentially parallel to said overall direction of flow; continuously withdrawing the processed tissue comprising the separated cells from the milling device (2).

Abstract: Disclosed is a hemostatic material, wherein a thrombin receptor activating agent is covalently coupled to a biocompatible matrix.

Abstract: The present invention provides a method of fixating a mesh implant to a tissue of a subject comprising attaching said mesh implant to said tissue, covering said mesh implant by an antiadhesive barrier, wherein said antiadhesive barrier is attached to said mesh implant by a biocompatible adhesive.

Abstract: This disclosure provides a method for measuring coagulation of blood or plasma samples using viscoelastic tests (VET) wherein the measuring is performed in the presence of immobilized endothelial cells.

Abstract: The present invention provides a method of fixating a mesh implant to a tissue of a subject comprising attaching said mesh implant to said tissue, covering said mesh implant by an antiadhesive barrier, wherein said antiadhesive barrier is attached to said mesh implant by a biocompatible adhesive.

Abstract: The present invention provides a method of fixating a mesh implant to a tissue of a subject comprising attaching said mesh implant to said tissue, covering said mesh implant by an antiadhesive barrier, wherein said antiadhesive barrier is attached to said mesh implant by a biocompatible adhesive.

Abstract: A laparoscopic tissue sealant spray apparatus and system having a laparoscopic tissue sealant spray assembly combined with a trocar assembly, the tissue sealant spray assembly having an elongate delivery tube. A spray outlet at a distal end of the elongate delivery tube may be rounded or angled. A ring member provided at the distal end of the elongate delivery tube directs a spray cone toward a portion of a target tissue site, and the spray cone may be repositioned to a different portion of the target tissue site by rotation of the elongate delivery tube. The trocar assembly includes a vent opening that connects to a venting valve member that provides a vent path which passively opens upon operation of the tissue sealant spray assembly, avoiding excessive pressure build-up within a body cavity.

Abstract: This disclosure provides a method for measuring coagulation of blood or plasma samples using viscoelastic tests (VET) wherein the measuring is performed in the presence of immobilised endothelial cells.

Abstract: Disclosed is a method for the production of three-dimensional silk products, wherein a three-dimensional silk product is treated with a silk solvent for a limited period of time so that a partial disintegration of the silk product is obtained whereafter the partially disintegrated silk product is re-stabilised with physical ?-sheet induction by a re-stabilising solution.

Abstract: The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein the recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least one, preferably two or more, lysine amine residues and/or the N-terminal amino acid of the fusion protein are carbamoylated. The carbamoylated EPO-Fc fusion proteins of the present invention having a reduced hematopoietic activity whereas the tissue regenerative activity, i.e. the nerve cell regenerative activity remains unaltered or is even enhanced as compared to unmodified EPO-Fc fusion proteins. The invention further relates to a process for the manufacture of such fusion proteins and to pharmaceutical compositions containing them, as well as to the use of such fusion proteins and pharmaceutical compositions for medical therapy.

Abstract: The present invention provides a method of fixating a mesh implant to a tissue of a subject comprising attaching said mesh implant to said tissue, covering said mesh implant by an antiadhesive barrier, wherein said antiadhesive barrier is attached to said mesh implant by a biocompatible adhesive.

Abstract: A tissue sealant applicator system includes a tissue sealant applicator having an elongate body forming a bore containing a tissue sealant component, a piston, and a spray adaptor in fluid communication with the bore and forming a gas flow path. The system also includes a control unit adapted to be connected to a gas source, and a first gas passageway connecting the gas flow path and the control unit. The applicator includes an actuating member cooperatively associated with the piston to eject the tissue sealant from the bore upon user actuation. The control unit is adapted to supply gas from the gas source to the first gas passageway essentially simultaneously with user actuation of the actuating member, and to permit the supply of gas to the spray adaptor from the gas source to continue to flow for a predetermined time delay after the user stops actuating the actuating member.

Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.

Abstract: The present invention relates to a polypeptide fragments of Fibroblast Growth Factor 2, wherein said fragments are adapted to bind to fibrinogen or to fibrin and/or increase cell proliferation, differentiation or migration. These fragments are suitable for promoting wound healing and/or hemostasis.

Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.